Company News2026-11-04

TJ Biopharma Announces Publication of Plonmarlimab Phase 2 Results in the Journal of Hematology & Oncology

Company News2026-10-26

TJ Biopharma Doses First Patient in Phase 1 Trial of TJ-C64B, a CLDN6x4-1BB Bispecific Antibody for CLDN6-Positive Solid Tumors

Company News2026-06-22

TJ Biopharma Announces NMPA Acceptance of Second BLA for Efmedaglutide Alfa in Type 2 Diabetes

Company News2026-04-20

TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region

Company News2025-10-14

TJ Biopharma Announces NMPA Acceptance of BLA for Efmedaglutide Alfa in Obesity

Company News2025-04-15

TJ Biopharma Announces Completion of Patient Enrollment in Phase 2 Clinical Study of Uliledlimab for NSCLC

Company News2025-04-07

TJ Biopharma Joins Biogen-Sponsored Phase 3 Multi-Regional Clinical Trials of Felzartamab in IgAN and PMN

Company News2025-01-10

TJ Biopharma Announces NMPA Acceptance of BLA for Felzartamab in Multiple Myeloma

Company News2024-12-09

TJ Biopharma and Jumpcan Jointly Announce China NMPA Acceptance of BLA for Eftansomatropin Alfa

• 1
• 2